Lv31
396 积分 2022-12-04 加入
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience
25天前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
25天前
已完结
Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
1个月前
已完结
An early precursor CD8+ T cell that adapts to acute or chronic viral infection
1个月前
已完结
Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions
2个月前
已完结
Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges
2个月前
已完结
Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncology
2个月前
已完结
Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis
2个月前
已完结
Novel immunotherapeutic approaches in lung cancer: driving beyond programmed death-1/programmed death ligand-1 and cytotoxic T-lymphocyte-associated Protein-4
2个月前
已完结
Résistance à l’immunothérapie dans le CBNPC : état des connaissances actuelles
2个月前
已关闭
皖公网安备34019202002308
